Sama Achieves B Corp Recertification and Releases 2024 Impact Report
Company's B Impact score climbed 19.9 points, while its 2024 initiatives cut carbon footprint 17.1%, shifted 23% of electricity to renewables, and deepened career-building programs for East African talent
SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Sama, the leader in purpose-built, responsible enterprise AI with agile data labeling for model training and performance evaluation, today announced its successful recertification as a Certified B Corporation™, marking a significant milestone in the company's commitment to balancing profit with purpose. The recertification comes alongside the release of Sama's 2024 Annual Impact Report, which details the company's progress across key environmental, social, and governance (ESG) initiatives.
Sama received an overall B Impact score of 118.4 from B Corp, up from 98.5 at initial certification in 2020. The new score affirms Sama's progress across governance, workforce development, community impact and environmental stewardship, exceeding the 80-point threshold required for B Corp status and more than doubling the median score of ordinary businesses. Full results of Sama's score can be found here.
B Corp companies are pioneers in establishing a fair, inclusive and regenerative economy, measured according to stringent criteria by B Lab across operations, including governance, community involvement, environmental impact and more.
'We are thrilled to recertify as B Corp, which offers independent proof that responsible AI can, and must, deliver measurable benefits to both people and planet,' said Wendy Gonzalez, CEO of Sama. 'Raising our score nearly 20 points reflects the thousands of decisions our teams made in recent years to embed ethics, transparency and sustainability deep into our business model.'
Sama's recently published 2024 Impact Report details a year of accelerated stakeholder value that included:
Sama was recently recognized as one of the top three Inspiring Workplaces in 2025 across the Middle East and Africa, one of only two tech companies and the sole data-annotation provider on the list. The company was also recognized by Newsweek on its Greatest Workplaces for Women and Greatest Workplaces for Inclusion & Diversity lists.
About B Lab Africa
B Lab Africa is transforming the economy to benefit all people, communities, and the planet. A leader in economic systems change, our global network creates standards, policies, and tools for business, and we certify companies-known as B Corps-who are leading the way. To date, our global community includes over 9,500 B Corps in 104 countries and 160 industries, and over 6,100 companies in Africa manage their impact with the B Impact Assessment and the SDG Action Manager. https://b-labafrica.net/
About Sama
Sama is a global leader in data annotation solutions for computer vision, generative AI and large language models. Our solutions minimize the risk of model failure and lower the total cost of ownership through an enterprise ready ML-powered platform and SamaIQ™, actionable data insights uncovered by proprietary algorithms and a highly skilled on-staff team of over 5,000 data experts. 40% of FAANG companies and other major Fortune 50 enterprises, including GM, Ford and Microsoft, trust Sama to help deliver industry-leading ML models.
Driven by a mission to expand opportunities for underserved individuals through the digital economy, Sama is a certified B-Corp and has impacted more than 69,000 people since 2008. An MIT-led Randomized Controlled Trial has validated that Sama's training and employment programs generated meaningful employment- and income-related outcomes. For more information, visit www.sama.com.
Sama Media Contact:
[email protected]
SOURCE: Sama
press release
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
4 hours ago
- Business Upturn
Biocon subsidiary gets Health Canada nod for YESAFILI
By Aman Shukla Published on June 27, 2025, 09:19 IST Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., has received a Notice of Compliance from Health Canada for YESAFILI™ (aflibercept), marking a significant milestone in the company's global biosimilars journey. The regulatory approval, granted on June 26, 2025, makes YESAFILI the first biosimilar to EYLEA® (aflibercept) to be approved in Canada. The product will be available in both vial and prefilled syringe forms (2 mg/0.05 mL), with its commercial launch set for July 4, 2025. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor designed to treat several serious eye conditions. These include neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and visual impairment due to macular edema caused by retinal vein occlusion (CRVO and BRVO), as well as myopic choroidal neovascularization (myopic CNV). The approval is backed by a robust data package encompassing analytical, nonclinical, and clinical studies. Health Canada concluded that YESAFILI matches EYLEA in quality, safety, and effectiveness, with no clinically meaningful differences. This milestone not only reinforces Biocon Biologics' capabilities in developing high-quality biosimilars but also enhances patient access to affordable treatment options in Canada. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at


Business Upturn
11 hours ago
- Business Upturn
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025 Marks the first submitted Clinical Trial Application (CTA) advancing ProQR's Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) — ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases. 'The submission of this CTA marks a significant milestone for ProQR, representing the first to advance our Axiomer RNA editing platform and pipeline into clinical development,' said Cristina Lopez Lopez, MD, PhD Chief Medical Officer of ProQR. 'This step brings us into the clinic with AX-0810 as we initiate a Phase 1 study to evaluate safety and target engagement in healthy volunteers. Cholestatic liver diseases represent an area of high unmet medical need and by targeting NTCP, AX-0810 introduces a novel therapeutic approach underpinned by human genetics and compelling preclinical data.' The proposed Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AX-0810 in healthy adult volunteers. The study will also explore biomarkers to assess early signals of target engagement. Pending regulatory clearance, the study is expected to commence at a single site in the Netherlands with initial data anticipated in Q4 2025. About AX-0810 AX-0810 is an investigational GalNac-delivered RNA editing oligonucleotide designed to treat cholestatic liver disease by targeting NTCP. These diseases are driven by toxic bile acid accumulation due to impaired bile flow, leading to progressive liver damage. AX-0810 offers a novel therapeutic approach by selectively modulating NTCP function, which decreases bile acid reuptake into the liver. This mechanism is supported by human genetics data showing that naturally occurring NTCP variants safety reduce bile acid reuptake, reinforcing the potential of NTCP modulation by ADAR-mediated RNA editing to improve liver health and alter the course of cholestatic disease. About Axiomer™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer 'Editing Oligonucleotides', or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease. About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell's own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Learn more about ProQR at Forward Looking Statements for ProQR This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'continue,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'look forward to', 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our business, ; our Axiomer™ RNA editing technology platform, including the continued development and advancement of our Axiomer platform, the advancement of AX-0810 to clinical trials, including the timing of, and our ability to obtain regulatory clearance; our expectations regarding the initiation of the planned Phase 1 clinical study of AX-0810 in the Netherlands, including our ability to recruit for and complete the study, and the anticipated timing of initial data in Q4 2025; the plan, timing, progress and results of our preclinical studies, planned clinical trials and other development activities, including the release of data related thereto, and the potential of our technologies and product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers or suppliers to supply materials for research and development and the risk of supply interruption or delays from suppliers or contract manufacturers; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. ProQR Therapeutics N.V. Investor and media contact:Sarah KielyProQR Therapeutics N.V.T: +1 617 599 6228 [email protected] or Investor contact: Peter KelleherLifeSci AdvisorsT: +1 617 430 7579 [email protected]


Business Wire
12 hours ago
- Business Wire
Caesars Entertainment Celebrates the Launch of Remote Reels ™, Delivering an Unmatched Casino Floor Experience to Caesars Palace Online Casino Players
BUSINESS WIRE)--Caesars Entertainment, Inc. (NASDAQ: CZR) ('Caesars') today celebrated the launch of Remote Reels ™ at Tropicana Atlantic City, an innovative online casino enhancement that connects live slot gameplay from the casino floor directly to Caesars Palace Online Casino on mobile and desktop. This launch marks a major milestone in Caesars' continued efforts to bring a land-based casino experience to its online casino platforms by bringing top titles that are typically found on-site at Caesars Rewards destinations to players in this remote-to-cabinet format for the first time ever. Players can choose from a range of popular physical slot machines located inside the Remote Reels ™ studio at Tropicana Atlantic City and play them directly on their mobile devices. Situated directly on the casino floor at Tropicana Atlantic City, the 937-square-foot Remote Reels™ studio, created in partnership with Awager, offers a thrilling new way to experience live slot action. Enclosed in glass walls, the studio features 25 slot machines that allow guests 21 and older to spin the reels via the Caesars Palace Online Casino app and play them remotely in real time. The studio is filled with popular titles from premier operators Light & Wonder and Aristocrat that are also available to customers at Caesars Rewards destinations across North America. "We're proud to be the first online casino operator to have premier titles such as Huff N' Even More Puff, Mo' Mummy Valley of Riches, Mo' Mummy Mighty Pyramid and Buffalo Triple Boost in a remote-to-cabinet play format,' said Matthew Sunderland, Senior Vice President and Chief iGaming Officer at Caesars Digital. 'The debut of our state-of-the-art Remote Reels™ studio inside Tropicana Atlantic City is the latest example of the innovation we aim to deliver to our online casino players and represents the perfect blend of the familiar feeling of slot play on a casino floor at one of our Caesars Rewards destinations with a fully mobile experience.' 'The stunning new Remote Reels™ studio adds another exciting component to the Tropicana Atlantic City experience for our guests and players,' said Joseph Giunta, Senior Vice President and General Manager of Tropicana Atlantic City. 'We're proud to showcase this immersive space in the heart of our casino and give our online players the thrill of Atlantic City from the comfort of their own homes.' To commemorate the exciting launch of Remote Reels ™, Caesars hosted popular online casino influencer, Slot Hopper at Tropicana Atlantic City to place the ceremonial first spin via a mobile device and provided a special look at the new technology for local media. 'We are incredibly proud to partner with Caesars Entertainment and Caesars Digital for the debut of Remote Reels™,' said Roy Greenbaum, Co-Founder & CEO of Awager. 'Bringing land-based play online is at the heart of our mission to deliver a truly authentic, immersive casino experience straight to players' devices. Streaming live from the iconic Tropicana Atlantic City underscores the unique entertainment value we offer our partners. The industry has been waiting for an innovation like this, and we're proud to launch it with a prominent brand like Caesars.' The launch of Remote Reels ™ marks the latest innovation for Caesars' online casino platforms, which features Caesars Palace Online Casino, Caesars Sportsbook & Casino, Horseshoe Online Casino, Tropicana Online Casino, and WSOP Online. Last month, The Company celebrated its first online casino title fully developed by its newly established in-house games studio, with the launch of Caesars Palace Signature Multihand Blackjack Surrender. Earlier this year, The Company also debuted a branded live-dealer studio inside Tropicana Atlantic City, marking the first of such inside a Caesars Rewards destination and its second branded studio in operation. Those 21 and older can download the Caesars Palace Online Casino app on iOS or Android, or by visiting the platform on desktop. Caesars Palace Online Casino, Horseshoe Online Casino, and Caesars Sportsbook & Casino are available for players 21 and older in New Jersey, Pennsylvania, Michigan, Ontario, and West Virginia. All online casino platforms are conveniently linked with Caesars Rewards, the industry-leading loyalty program. U.S. players can earn Caesars Rewards Credits, redeemable for unforgettable experiences at over 50 world-class Caesars destinations across North America Caesars Entertainment is an industry leader in Responsible Gaming, known for pioneering Responsible Gaming awareness and education. In 1989, Caesars became the first commercial casino company to address problem gambling by launching the industry's first Responsible Gaming program, Project 21. Today, the Company's commitment to ensuring all players are aware of Responsible Gaming resources remains steadfast and spans all of Caesars' digital platforms and world-class destinations in which it operates. Caesars Entertainment proudly enforces an enhanced 21+ gaming policy that prevents individuals under the age of 21 from using Caesars Rewards and restricts access to its gaming products for individuals under the age of 21. In March 2024, Caesars Sportsbook received the prestigious RG Check accreditation from the Responsible Gambling Council in Ontario, Canada, which recognizes companies that achieve the highest standards for their Responsible Gaming practices. Just a few months later, the Company was awarded the National Council on Problem Gambling's award for Corporate Social Responsibility. For more information about Caesars Entertainment's Responsible Gaming program, please visit About Caesars Entertainment, Inc. Caesars Entertainment, Inc. (NASDAQ: CZR) is the largest casino entertainment company in the U.S. and one of the world's most diversified casino entertainment providers. Since its beginning in Reno, NV, in 1937, Caesars Entertainment, Inc. has grown through the development of new resorts, expansions and acquisitions. Caesars Entertainment, Inc.'s resorts operate primarily under the Caesars®, Harrah's®, Horseshoe® and Eldorado® brand names. Caesars Entertainment, Inc. offers diversified gaming, entertainment and hospitality amenities, one-of-a-kind destinations, and a full suite of mobile and online gaming and sports betting experiences. All tied to its industry-leading Caesars Rewards® loyalty program, the company focuses on building value with its guests through a unique combination of impeccable service, operational excellence and technology leadership. Caesars is committed to its Team Members, suppliers, communities and the environment through its PEOPLE PLANET PLAY framework. Know When To Stop Before You Start.® Gambling Problem? Call 1-800-522-4700. For more information, please visit If you think you or someone you care about may have a gambling problem, call 1-877-770-STOP (1-877-770-7867). About Awager Awager is a pioneering iGaming technology company dedicated to redefining the online casino experience by bridging the gap between land-based casinos and virtual play. Through its proprietary and patented technology, Awager enables players to remotely access and interact with real, physical slot machines and electronic table games located on casino floors, delivering an authentic and immersive live gaming experience directly to their mobile devices and desktops. Awager's innovative solutions create dedicated broadcast studios for partners, complete with real-time camera views, sound captures, and cutting-edge interfaces, ensuring a trusted and familiar environment for players worldwide. Committed to revolutionizing the industry, Awager provides a unique and engaging omni-channel solution that brings the excitement of traditional casino play to the digital realm. Online Casino apps & websites available in MI, NJ, PA, WV and ON only. Must be 21+. See or for full terms. Void where prohibited. Know When To Stop Before You Start®. Gambling Problem? MI, NJ, WV, PA (Affiliated with Harrah's Philadelphia): If you or someone you know has a gambling problem, crisis counseling and referral services can be accessed by calling 1-800-GAMBLER (1-800-426-2537) or WV: Visit ON: Visit or call 1-866-531-2600 or text CONNEX to 247247. Accruing Caesars Rewards credits is currently not available in Ontario when using Caesars Sportsbook & Casino, Caesars Palace Online Casino, and Horseshoe Online Casino. ©2025, Caesars Entertainment